FOLOTYN

This brand name is authorized in Australia, Canada, Singapore, United States

Active ingredients

The drug FOLOTYN contains one active pharmaceutical ingredient (API):

1 Pralatrexate UNII A8Q8I19Q20 - PRALATREXATE

Pralatrexate is a folate analog metabolic inhibitor that competitively inhibits dihydrofolate reductase. It is also a competitive inhibitor for polyglutamylation by the enzyme folylpolyglutamyl synthetase. This inhibition results in the depletion of thymidine and other biological molecules the synthesis of which depends on single carbon transfer. Pralatrexate is used for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Read about Pralatrexate

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
FOLOTYN Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01BA05		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BA Folic acid analogues
Discover more medicines within L01BA05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 11271F, 11272G, 11278N, 11293J
Country: CA	Health Products and Food Branch	Identifier(s): 02481820
Country: SG	Health Sciences Authority	Identifier(s): 14544P
Country: US	FDA, National Drug Code	Identifier(s): 48818-001, 72893-003, 72893-005